Activation of human T lymphocytes by bryostatin

A. D. Hess, M. K. Silanskis, A. H. Esa, George Pettit, W. S. May

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

The immunologic effects of bryostatin (Bryo), a PKC activator with antineoplastic activity, were assessed and compared to PMA. Bryo induced IL-2R expression on CD4+ and CD8+ human T lymphocytes with a dose response comparable to PMA. However, Bryo induced only a marginal proliferative response as compared with the vigorous response induced by PMA. Bryo mediated functional receptor expression because the proliferative response was enhanced by addition of rIL-2. Furthermore, the proliferative response was inhibited by the relatively specific Ca+, phospholipid-dependent protein kinase (PKC) inhibitor, H-7, indicating a role of PKC in Bryo-induced activation. Addition of the calcium ionophore, ionomycin, to Bryo-stimulated lymphocytes resulted in the production and secretion of IL-2 with a concomitant proliferative response. This effect of the calcium ionophore could be inhibited by cyclosporine with identical results obtained in PMA-stimulated cultures. A most intriguing finding was that Bryo could effectively antagonize PMA-induced T cell proliferation. Although this mechanism of inhibition is unclear, a discussion with respect to differential effects on potential intracellular PKC isoforms is provided. These studies indicated that Bryo has potent immunopotentiating properties that share some similar effects of the phorbol ester, PMA, but offers the additional property of modulating other phorbol ester effects on proliferation.

Original languageEnglish (US)
Pages (from-to)3263-3269
Number of pages7
JournalJournal of Immunology
Volume141
Issue number10
StatePublished - 1988
Externally publishedYes

Fingerprint

Bryostatins
T-Lymphocytes
Calcium Ionophores
Phorbol Esters
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
Ionomycin
Protein Kinase Inhibitors
Antineoplastic Agents
Cyclosporine
Interleukin-2
Phospholipids
Protein Isoforms
Cell Proliferation
Lymphocytes

ASJC Scopus subject areas

  • Immunology

Cite this

Hess, A. D., Silanskis, M. K., Esa, A. H., Pettit, G., & May, W. S. (1988). Activation of human T lymphocytes by bryostatin. Journal of Immunology, 141(10), 3263-3269.

Activation of human T lymphocytes by bryostatin. / Hess, A. D.; Silanskis, M. K.; Esa, A. H.; Pettit, George; May, W. S.

In: Journal of Immunology, Vol. 141, No. 10, 1988, p. 3263-3269.

Research output: Contribution to journalArticle

Hess, AD, Silanskis, MK, Esa, AH, Pettit, G & May, WS 1988, 'Activation of human T lymphocytes by bryostatin', Journal of Immunology, vol. 141, no. 10, pp. 3263-3269.
Hess AD, Silanskis MK, Esa AH, Pettit G, May WS. Activation of human T lymphocytes by bryostatin. Journal of Immunology. 1988;141(10):3263-3269.
Hess, A. D. ; Silanskis, M. K. ; Esa, A. H. ; Pettit, George ; May, W. S. / Activation of human T lymphocytes by bryostatin. In: Journal of Immunology. 1988 ; Vol. 141, No. 10. pp. 3263-3269.
@article{a0d790dff2784618a65aa2c96be695b9,
title = "Activation of human T lymphocytes by bryostatin",
abstract = "The immunologic effects of bryostatin (Bryo), a PKC activator with antineoplastic activity, were assessed and compared to PMA. Bryo induced IL-2R expression on CD4+ and CD8+ human T lymphocytes with a dose response comparable to PMA. However, Bryo induced only a marginal proliferative response as compared with the vigorous response induced by PMA. Bryo mediated functional receptor expression because the proliferative response was enhanced by addition of rIL-2. Furthermore, the proliferative response was inhibited by the relatively specific Ca+, phospholipid-dependent protein kinase (PKC) inhibitor, H-7, indicating a role of PKC in Bryo-induced activation. Addition of the calcium ionophore, ionomycin, to Bryo-stimulated lymphocytes resulted in the production and secretion of IL-2 with a concomitant proliferative response. This effect of the calcium ionophore could be inhibited by cyclosporine with identical results obtained in PMA-stimulated cultures. A most intriguing finding was that Bryo could effectively antagonize PMA-induced T cell proliferation. Although this mechanism of inhibition is unclear, a discussion with respect to differential effects on potential intracellular PKC isoforms is provided. These studies indicated that Bryo has potent immunopotentiating properties that share some similar effects of the phorbol ester, PMA, but offers the additional property of modulating other phorbol ester effects on proliferation.",
author = "Hess, {A. D.} and Silanskis, {M. K.} and Esa, {A. H.} and George Pettit and May, {W. S.}",
year = "1988",
language = "English (US)",
volume = "141",
pages = "3263--3269",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "10",

}

TY - JOUR

T1 - Activation of human T lymphocytes by bryostatin

AU - Hess, A. D.

AU - Silanskis, M. K.

AU - Esa, A. H.

AU - Pettit, George

AU - May, W. S.

PY - 1988

Y1 - 1988

N2 - The immunologic effects of bryostatin (Bryo), a PKC activator with antineoplastic activity, were assessed and compared to PMA. Bryo induced IL-2R expression on CD4+ and CD8+ human T lymphocytes with a dose response comparable to PMA. However, Bryo induced only a marginal proliferative response as compared with the vigorous response induced by PMA. Bryo mediated functional receptor expression because the proliferative response was enhanced by addition of rIL-2. Furthermore, the proliferative response was inhibited by the relatively specific Ca+, phospholipid-dependent protein kinase (PKC) inhibitor, H-7, indicating a role of PKC in Bryo-induced activation. Addition of the calcium ionophore, ionomycin, to Bryo-stimulated lymphocytes resulted in the production and secretion of IL-2 with a concomitant proliferative response. This effect of the calcium ionophore could be inhibited by cyclosporine with identical results obtained in PMA-stimulated cultures. A most intriguing finding was that Bryo could effectively antagonize PMA-induced T cell proliferation. Although this mechanism of inhibition is unclear, a discussion with respect to differential effects on potential intracellular PKC isoforms is provided. These studies indicated that Bryo has potent immunopotentiating properties that share some similar effects of the phorbol ester, PMA, but offers the additional property of modulating other phorbol ester effects on proliferation.

AB - The immunologic effects of bryostatin (Bryo), a PKC activator with antineoplastic activity, were assessed and compared to PMA. Bryo induced IL-2R expression on CD4+ and CD8+ human T lymphocytes with a dose response comparable to PMA. However, Bryo induced only a marginal proliferative response as compared with the vigorous response induced by PMA. Bryo mediated functional receptor expression because the proliferative response was enhanced by addition of rIL-2. Furthermore, the proliferative response was inhibited by the relatively specific Ca+, phospholipid-dependent protein kinase (PKC) inhibitor, H-7, indicating a role of PKC in Bryo-induced activation. Addition of the calcium ionophore, ionomycin, to Bryo-stimulated lymphocytes resulted in the production and secretion of IL-2 with a concomitant proliferative response. This effect of the calcium ionophore could be inhibited by cyclosporine with identical results obtained in PMA-stimulated cultures. A most intriguing finding was that Bryo could effectively antagonize PMA-induced T cell proliferation. Although this mechanism of inhibition is unclear, a discussion with respect to differential effects on potential intracellular PKC isoforms is provided. These studies indicated that Bryo has potent immunopotentiating properties that share some similar effects of the phorbol ester, PMA, but offers the additional property of modulating other phorbol ester effects on proliferation.

UR - http://www.scopus.com/inward/record.url?scp=0023698185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023698185&partnerID=8YFLogxK

M3 - Article

C2 - 3263418

AN - SCOPUS:0023698185

VL - 141

SP - 3263

EP - 3269

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 10

ER -